Welcome to our dedicated page for Supernus Pharma SEC filings (Ticker: SUPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Supernus Pharmaceuticals, Inc. (SUPN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Supernus is a biopharmaceutical company focused on developing and commercializing products for central nervous system (CNS) diseases, and its filings offer detailed insight into its commercial portfolio, collaborations, and pipeline.
Supernus’s current reports on Form 8-K cover a range of material events. These include announcements of quarterly financial results, where the company reports total revenues, net product sales for CNS therapies such as Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ONAPGO, and other products, as well as royalty, licensing and other revenues and collaboration revenue from ZURZUVAE. Filings also describe non-GAAP measures like adjusted operating earnings and revenues excluding certain legacy products.
Other 8-K filings document corporate transactions, notably the acquisition of Sage Therapeutics, Inc. Supernus details the merger structure, consideration, contingent value rights (CVRs) tied to ZURZUVAE milestones, and the integration of Sage as a wholly owned subsidiary. These filings also outline the collaboration economics with Biogen Inc. related to ZURZUVAE, an oral treatment for postpartum depression.
Additional disclosures address operational updates, such as supply constraints for ONAPGO due to stronger than expected demand and the company’s decision to prioritize existing patients while working to rebuild inventory. Filings also announce upcoming earnings release dates and conference calls, reinforcing the company’s regular reporting cadence.
On Stock Titan, investors can use AI-powered tools to read concise summaries of Supernus’s 8-Ks and other SEC documents, quickly understand key points about CNS product performance, collaboration revenue, acquisitions, and pipeline developments, and identify items such as contingent value rights or other material agreements without manually parsing lengthy filings.
Supernus Pharmaceuticals Senior Vice-President & CFO Timothy C. Dec reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 25, 2,500 RSUs were settled into 2,500 shares of common stock, and 1,279 of those shares were withheld by the company to cover tax obligations at a price of $50.69 per share. After these transactions, Dec directly owned 5,115 shares of common stock. Each RSU represents one share of common stock and vests in four equal annual installments beginning on February 23, 2024.
SUPERNUS PHARMACEUTICALS, INC. Sr. VP of IP and CSO Padmanabh P. Bhatt reported equity award-related transactions. A grant of 1,250 shares of common stock was acquired at a price of $0.00, tied to restricted stock units that convert into one share each upon vesting.
On the same date, 1,250 restricted stock units were disposed back to the issuer and 650 shares of common stock at $50.69 were withheld by the company to cover tax obligations in connection with RSU vesting, rather than sold on the open market.
Supernus Pharmaceuticals executive Jonathan Rubin, SVP and Chief Medical Officer, reported equity award activity and related share transactions. He disposed of 1,250 restricted stock units back to the issuer and simultaneously acquired 1,250 shares of common stock at $0.00 per share as a grant. To cover taxes on the RSU vesting, 675 shares of common stock were automatically disposed of at $50.69 per share, with the company withholding these shares to satisfy tax obligations. Following these transactions, Rubin directly owned 13,341 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. Senior Vice-President & CFO Timothy C. Dec reported multiple equity compensation transactions on February 24, 2026. Restricted stock units were disposed back to the issuer as they vested, and related common stock was acquired. Some common shares were then delivered to cover tax withholding obligations at prices around $51 per share. Footnotes explain that each restricted stock unit converts into one common share and that various RSU grants vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025.
SUPERNUS PHARMACEUTICALS, INC. director Charles W. Newhall III reported routine equity transactions. On February 24, 2026, 4,475 restricted stock units were disposed to the issuer and an equal 4,475 shares of common stock were acquired at no cost, bringing his direct holdings to 124,119 shares. Footnotes state each unit converts into one share, with vesting and settlement scheduled for February 19, 2026.
Supernus Pharmaceuticals director Frederick M. Hudson reported a routine equity award conversion. On February 24, 2026, 4,475 restricted stock units were disposed back to the issuer at no cost, and he simultaneously acquired 4,475 shares of common stock at no cost.
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting, with settlement in stock scheduled to occur on February 19, 2026. After these transactions, Hudson directly holds 65,782 shares of common stock, reflecting a shift from derivative RSU holdings into outright share ownership rather than an open-market purchase or sale.
SUPERNUS PHARMACEUTICALS, INC. director Carrolee Barlow reported routine equity award activity. On February 24, 2026, 4,475 restricted stock units were disposed of back to the company as they converted into 4,475 shares of common stock at no cash cost. After this grant/award acquisition, Barlow directly owns 27,045 shares of Supernus common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Padmanabh P. Bhatt reported a series of equity-related transactions in connection with restricted stock units and common stock on February 24, 2026. He disposed of restricted stock units back to the issuer in amounts of 1,125, 750 and 1,250 units, each representing the right to receive one share of common stock upon vesting.
On the same date, he acquired common stock through grants or awards of 1,125, 750 and 1,250 shares. The filing also shows tax-withholding dispositions of 581, 354 and 646 common shares, with shares withheld by the company at prices of $51.35 and $50.86 per share to satisfy tax obligations upon RSU vesting. Certain RSUs vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, and are settled in common stock.
SUPERNUS PHARMACEUTICALS, INC. senior vice president Frank Mottola reported a mix of equity award activity and related share dispositions. On February 24, 2026, several restricted stock unit (RSU) awards vested, and RSUs totaling 1,125, 750 and 1,250 units were disposed of back to the company. Each RSU represents the right to receive one share of Supernus common stock upon vesting.
On the same date, Mottola received three common stock grants of 1,125, 750 and 1,250 shares at no cost, while 603, 368 and 670 common shares were delivered back to the company at prices of $51.35 and $50.86 to satisfy tax withholding obligations tied to the RSU vesting. The RSU awards vest in four equal annual installments beginning on February 19, 2026, February 22, 2023 and February 22, 2025, as applicable.
SUPERNUS PHARMACEUTICALS SVP and Chief Medical Officer Jonathan Rubin reported multiple equity compensation events. On February 24, 2026, restricted stock units were disposed back to the company as they vested, and corresponding shares of common stock were acquired. Some of these new shares were withheld by the company to cover tax obligations. The RSUs each convert into one share of common stock and vest in four equal annual installments beginning on February 19, 2026, February 22, 2023, and February 22, 2025, depending on the grant.